HOWL (Werewolf Therapeutics) Cash Flow from Others: $2.40 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HOWL Werewolf Therapeutics Inc HOWL
18 GF Score
Price $0.86
! 3 Warning Signs
View Full Analysis

What is Werewolf Therapeutics Cash Flow from Others?

Werewolf Therapeutics HOWL -2.07% 18 Cash Flow from Others is $2.40 Mil as of Jun. 2026. GuruFocus rates HOWL with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Werewolf Therapeutics's cash flow from others for the three months ended in Jun. 2026 was $2.60 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Jun. 2026 was $2.40 Mil.

Werewolf Therapeutics Cash Flow from Others Related Terms

Werewolf Therapeutics Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for Werewolf Therapeutics's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Werewolf Therapeutics Cash Flow from Others Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial 0.52 2.17 0.88 1.16 0.86

Werewolf Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.72 -1.07 0.14 2.60
HOWL
18GF Score
Werewolf Therapeutics Inc HOWL
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Werewolf Therapeutics Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.40 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of $2.40 Mil mean?
Werewolf Therapeutics (HOWL) has a Cash Flow from Others of $2.40 Mil as of Jun. 2026. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Werewolf Therapeutics and its competitors.
Is Werewolf Therapeutics' Cash Flow from Others too high?
Werewolf Therapeutics' current Cash Flow from Others is $2.40 Mil. Overall, Werewolf Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' Cash Flow from Others compare to CVM and MRKR?
Werewolf Therapeutics' Cash Flow from Others of $2.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Biotechnology company?
A good Cash Flow from Others depends on the Biotechnology industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Werewolf Therapeutics and its competitors. Werewolf Therapeutics's current Cash Flow from Others is $2.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Werewolf Therapeutics (HOWL) has a current Cash Flow from Others of $2.40 Mil. The current Cash Flow from Others is $2.40 Mil. Werewolf Therapeutics' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current Cash Flow from Others is $2.40 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Werewolf Therapeutics Business Description

Address 200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
18GF Score

Get the complete analysis for HOWL

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.86
Price